Advanced

Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease

Wesnes, K.; Edgar, C.; Andreasen, N.; Annas, P.; Basun, H.; Lannfelt, L.; Zetterberg, H.; Blennow, K. and Minthon, Lennart LU (2010) In Acta Neurologica Scandinavica 122(4). p.270-277
Abstract
Objectives - Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) has become a standard clinical trials outcome for cognition, but has been recognized as deficient in areas including coverage of cognitive domains, sensitivity and standardization. Computerized test batteries may address some of these issues. The cognitive drug research computerized assessment (CDR) system is validated in Alzheimer's disease (AD). This study was designed to further evaluate validity in relation to ADAS-Cog, mini mental state examination (MMSE) and cerebrospinal fluid (CSF) biomarkers and psychometric properties, in a population of Alzheimer's patients on stable anticholinesterase treatment. Materials and methods - Patients completed cognition... (More)
Objectives - Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) has become a standard clinical trials outcome for cognition, but has been recognized as deficient in areas including coverage of cognitive domains, sensitivity and standardization. Computerized test batteries may address some of these issues. The cognitive drug research computerized assessment (CDR) system is validated in Alzheimer's disease (AD). This study was designed to further evaluate validity in relation to ADAS-Cog, mini mental state examination (MMSE) and cerebrospinal fluid (CSF) biomarkers and psychometric properties, in a population of Alzheimer's patients on stable anticholinesterase treatment. Materials and methods - Patients completed cognition assessments, CSF and blood sampling at baseline and 6 months later. Data for 65 patients were evaluated. Results - The CDR system demonstrated good psychometric properties in this population. Measures of psychomotor speed showed possible sensitivity to decline over 6 months. Conclusions - There are a number of methodological problems with current cognition assessment methodology for clinical trials. Computerized measures and in particular millisecond reaction time measures, may address many of these issues. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease assessment scale-cognitive subscale, system, cognitive drug research, computerized, cognition, Alzheimer's disease, mini, mental state examination
in
Acta Neurologica Scandinavica
volume
122
issue
4
pages
270 - 277
publisher
Wiley-Blackwell
external identifiers
  • wos:000281631600008
  • scopus:77956413330
ISSN
1600-0404
DOI
10.1111/j.1600-0404.2009.01309.x
language
English
LU publication?
yes
id
4fdb859d-1490-4249-b78b-a460cb4e73d3 (old id 1697905)
date added to LUP
2010-10-22 11:42:52
date last changed
2018-05-29 11:08:06
@article{4fdb859d-1490-4249-b78b-a460cb4e73d3,
  abstract     = {Objectives - Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) has become a standard clinical trials outcome for cognition, but has been recognized as deficient in areas including coverage of cognitive domains, sensitivity and standardization. Computerized test batteries may address some of these issues. The cognitive drug research computerized assessment (CDR) system is validated in Alzheimer's disease (AD). This study was designed to further evaluate validity in relation to ADAS-Cog, mini mental state examination (MMSE) and cerebrospinal fluid (CSF) biomarkers and psychometric properties, in a population of Alzheimer's patients on stable anticholinesterase treatment. Materials and methods - Patients completed cognition assessments, CSF and blood sampling at baseline and 6 months later. Data for 65 patients were evaluated. Results - The CDR system demonstrated good psychometric properties in this population. Measures of psychomotor speed showed possible sensitivity to decline over 6 months. Conclusions - There are a number of methodological problems with current cognition assessment methodology for clinical trials. Computerized measures and in particular millisecond reaction time measures, may address many of these issues.},
  author       = {Wesnes, K. and Edgar, C. and Andreasen, N. and Annas, P. and Basun, H. and Lannfelt, L. and Zetterberg, H. and Blennow, K. and Minthon, Lennart},
  issn         = {1600-0404},
  keyword      = {Alzheimer's disease assessment scale-cognitive subscale,system,cognitive drug research,computerized,cognition,Alzheimer's disease,mini,mental state examination},
  language     = {eng},
  number       = {4},
  pages        = {270--277},
  publisher    = {Wiley-Blackwell},
  series       = {Acta Neurologica Scandinavica},
  title        = {Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease},
  url          = {http://dx.doi.org/10.1111/j.1600-0404.2009.01309.x},
  volume       = {122},
  year         = {2010},
}